Mar 16, 2023 7:05am EDT IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
Mar 09, 2023 7:05am EST IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
Feb 13, 2023 7:05am EST IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
Jan 08, 2023 5:00pm EST IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
Dec 20, 2022 12:37pm EST IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 16, 2022 8:00am EST IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 15, 2022 7:05am EST IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL